drugset
Drugs / bempikibart
last change Sep 2026 re-read 3 minutes ago

bempikibart

also known as ADX-914 · BMS-986265

Monoclonal antibody

Developed for
alopecia areata · atopic eczema
Investigated by
Q32 Bio Inc.

Trials 3

today NCT06018428 · Ph 2 NCT05509023 · Ph 2 NCT04485481 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04485481 Sep 2020 → Jan 2022 — Q32 Bio Inc. Completed No outcome recorded
Phase 22 trials · 1 missed
Phase 2 NCT06018428 Sep 2023 → Jun 2026 overdue alopecia areata Q32 Bio Inc. Active not recruiting No outcome recorded
Phase 2 NCT05509023 Sep 2022 → Dec 2024 overdue atopic eczema Q32 Bio Inc. Active not recruiting Missed primary

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2026-07-13 Q32 Bio Inc. Results Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata q32bio.com ↗
Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis
2025-04-30 Q32 Bio Inc. Regulatory Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata q32bio.com ↗
2025-03-08 Q32 Bio Inc. Results Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting q32bio.com ↗
2024-12-10 Q32 Bio Inc. Results Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program q32bio.com ↗
SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response

All press releases naming this drug 13 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as bempikibart ClinicalTrials.gov intervention name — accepted as the source's own label NCT06018428 ↗
Known as ADX-914 “bempikibart (ADX-914)” NCT06018428 ↗
2

NCT05509023 ↗

NCT04485481 ↗
Known as BMS-986265 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095301 ↗
Modality Monoclonal antibody — CHEMBL5095301 ↗
Route Subcutaneous “ADX-914 single SC dose” NCT04485481 ↗